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Abstract
According to disease burden estimates, leishmaniasis ranks third in disease burden in disability-adjusted life years caused by neglected
tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the
attention that would be justiﬁed seeing its importance. This is especially apparent in the unnecessarily and unacceptably poor access to
timely and appropriate treatment for patients. To our knowledge, this is the ﬁrst publication that addresses the major issues associated
with poor access to drugs for leishmaniasis and that outlines a number of feasible and practical solutions.
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Introduction
The leishmaniases are a complex of diseases caused by the
intracellular protozoan Leishmania. They are widely spread
and their disease burden is high, with 350 million people
considered at risk. There are an estimated 1.5–2 million new
cases per year, up to 500 000 of which are visceral and
1 500 000 are (muco-)cutaneous. All of these ﬁgures are
provisionally accepted [1] but currently under revision.
Whereas cutaneous leishmaniasis (CL) has a tendency to
spontaneously self-heal with resulting scars, visceral leishman-
iasis (VL) is fatal when left untreated, causing a global annual
mortality estimated at 59 000 (35 000 men and 24 000
women); in some areas, because of gender inequality, the
case fatality rate is three times higher in women than in
men. The disease burden is calculated at 2 356 000 disability-
adjusted life years (946 000 in women and 1 410 000 in
men), a signiﬁcant rank among communicable diseases [2].
In the last 20 years, considerable progress has been made
in the development of highly effective, safe and easily applied
diagnostics and treatments [3]. Yet, most patients still have
little or no access to care. Most of the endemic countries are
very poor, do not recognize leishmaniasis as a health priority
and do not maintain functioning control programmes. Very
few non-government organizations (NGOs) are active in the
control of leishmaniasis, and leishmaniasis does not receive
noteworthy attention from international donors. Poor access
to care for leishmaniasis remains one of the most important
barriers to control. We estimate that over 50% of patients
do not have access to appropriate diagnosis and treatment
today. With the lack of functioning control programmes,
patients revert to the private sector, where, in order to
afford treatment, they are forced to sell valuable assets,
thereby signiﬁcantly increasing their level of poverty [4,5].
Weak or non-functioning health systems, widespread pov-
erty, little political commitment and major gaps in knowledge
all play a role in the lack of control of leishmaniasis and the
dire situation for patients today. However, it should not be
overlooked that poor access to drugs for leishmaniasis is
currently one of the main barriers for functioning control
programmes in the majority of countries with an important
leishmaniasis burden (India, Nepal, Bangladesh and the ende-
mic countries of East Africa). Despite considerable invest-
ments in time and energy of both WHO and NGOs, namely
Me´decins Sans Frontie`res, to reduce prices and increase
availability of drugs, a number of easily resolved factors
impeding drug access, caused by a lack of coordination,
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willingness and interest of pharmaceutical manufacturers and
the international community remain to be resolved. We will
discuss the major issues associated with poor access to
drugs for leishmaniasis and outline a number of feasible and
practical solutions.
Epidemiology, Impact and Geographical
Distribution
Depending on the transmission cycle VL and CL are consid-
ered either anthroponotic (AVL/ACL) or zoonotic (ZVL/
ZCL).
Anthroponotic VL is caused by Leishmania donovani and is
characterized by a clustered transmission. Its main distribu-
tion is in the Indian subcontinent where it accounts for 70%
of the burden of VL with over 300 000 annual cases. In East
Africa it causes around 50 000 annual cases, in the form of
epidemic outbreaks among displaced populations with a high
mortality rate. Post-kala-azar dermal leishmaniasis (PKDL),
which develops in 5–50% of AVL patients depending on geo-
graphical areas, requires lengthy and costly treatment with a
low efﬁcacy [6,7]. The most relevant factors determining the
spread of AVL are an increasing transmission in urban areas
with large numbers of immigrants living in poor conditions,
the breakdown of social and health structures, often as a
result of wars, malnutrition inducing weakening of the
immune system and ﬁnally, HIV–Leishmania co-infection,
which is now reported in 35 endemic countries. The HIV–VL
co-infection is characterized by frequent relapses and a high
fatality rate and cases are considered to constitute an impor-
tant infectious reservoir [5,8].
Zoonotic VL is caused by L. infantum and is widely distrib-
uted in Central Asia, Middle East, the Mediterranean and
Brazil. Up to 50 000 annual cases may be caused by this
form worldwide, with a scattered distribution.
In Central Asia, the Middle East, North Africa and some
Sub-Saharan countries, ZCL caused by L. major accounts for
c. 500 000 cases every year. Outbreaks are typical in rural
areas and depend on ﬂuctuations in the rodent population.
ACL caused by L. tropica is transmitted in urban zones and
affects around 400 000 patients annually. Massive outbreaks
have occurred in overcrowded suburbs with poor housing
and deteriorated environmental conditions [9]. ZCL caused
by L. aethiopica is present in Ethiopia and is the most
neglected form of CL despite 50 000 annual cases and a
potential serious clinical progression, including diffuse CL and
to a lesser degree mucocutaneous leishmaniasis.
In South America, c. 300 000 new cases of ZCL occur
annually. Leishmania braziliensis is responsible for nearly 90%
of all CL cases. Species belonging to the subgenus Viannia
(L. braziliensis, L. panamensis, L. peruviana and L. guyanensis)
are capable of causing mucocutaneous leishmaniasis. No or
incomplete treatment of CL is associated with the subse-
quent development of mucocutaneous leishmaniasis. It is esti-
mated that there c. 4000 new mucocutaneous leishmaniasis
cases occur every year [10]. The subgenus Leishmania groups
comprise two main species, L. mexicana, causing a form of
CL that heals spontaneously but can sometimes cause necro-
sis of the external ear (the ‘chiclero’ ulcer), and L. amazonen-
sis, which can in some cases manifest as diffuse CL in
patients with weak immune systems [10].
Although the leishmaniases affect 98 countries in the
world, it should be stressed that 90% of VL cases occur in
India, Bangladesh, Sudan, Brazil, Nepal and Ethiopia, and 90%
of CL cases occur in Afghanistan, Algeria, Ethiopia, Sudan,
Iran, Iraq, Saudi Arabia, Syria, Brazil and Peru [2,11].
Treatment Regimen for Leishmaniasis
Visceral leishmaniasis
Pentavalent antimonials (meglumine antimoniate and sodium
stibogluconate (SSG)) have been the standard ﬁrst-line treat-
ment of VL for the last seven decades. As these drugs are
toxic and ineffective in most of India [12], require long treat-
ment durations and are painful to administer, alternative
treatments are needed for control programmes. In the past
10 years, signiﬁcant progress has been made with the
approval of lipid formulations of amphotericin B, miltefosine
and paromomycin for the treatment of VL. Liposomal ampho-
tericin B (AmBisome; Gilead, Foster City, CA, USA) is by far
the safest and most effective drug because of its excellent
therapeutic index and long half-life, allowing for ultra-short
regimens [13,14]. Last year, a single dose of 10 mg/kg AmBi-
some was recommended by WHO as the preferred ﬁrst-line
treatment option for the Indian subcontinent [1,15]. This regi-
men is ultra-rapid, extremely safe and highly efﬁcacious and
opened a new dimension for large-scale control programmes.
Bangladesh, Nepal and India have agreed on a concerted effort
to eliminate VL by 2015 [16]. For the attack phase of this plan,
widespread use of single dose AmBisome is a highly attractive
approach because it does not require prolonged hospital
stays, allows for a minimal management of adverse effects and
has guaranteed compliance. It would enable a rapid reduction
of the disease burden and is therefore the best option for
reaching the elimination goal. Several combination regimens,
which have the advantages of shortening the treatment
duration and overall dose of drugs and reducing the probabil-
ity of selecting for drug-resistant parasites, have been
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recommended as an alternative choice for this region [17,18].
None of the above discussed new treatment options have yet
been rolled out in control programmes.
The combination of paromomycin and pentavalent antimo-
nials proved to be safe and efﬁcacious in East Africa [19] and
was recommended by WHO as ﬁrst-line treatment for this
region [1]. The roll out of this combination has been started.
Cutaneous leishmaniasis
Many different therapeutic interventions, including topical,
systemic and non-pharmacological treatments, have been
described [10] but the mainstay of treatment still consists of
intralesional injection of pentavalent antimonials. Systemic
antimony is used for severe and complex lesions.
Access to Drugs
Access to drugs is determined by factors such as drug
affordability, drug availability, proper forecasting, distribution
and storage, drug quality, drug legislation and pharmacovigi-
lance and user friendliness through appropriate packing and
information leaﬂets.
Drug affordability
In poverty-related diseases, drugs are often unaffordable for
individual patients as well as for control programmes in low-
income countries. Improving drug affordability is often possi-
ble through a joint effort by pharmaceutical companies and
WHO or NGOs, where companies can either donate the
drugs, develop preferential pricing schemes, or provide drugs
at production cost, and WHO or NGOs can provide ser-
vices such as coordination and proper distribution. The cost
of ensuring access to drugs is importantly larger than the
cost of the drugs alone. This has to be taken into consider-
ation when attempting to deﬁne optimal affordability. WHO
considers that for poverty-related diseases in low-income
countries, to implement efﬁcient control programmes even-
tually leading to elimination, drug donations that last until
elimination is achieved are an efﬁcient solution. Even a drug
free of charge can still be too expensive if all the obstacles
to it reaching the patients are considered. Examples of suc-
cessful donation schemes are the Merck Mectizan donation
programme where ivermectin is donated free of charge for
the treatment of onchocerciasis for as long as is needed and
the long-term commitment of sanoﬁ-aventis to the control
of human African trypanosomiasis, which includes drug dona-
tions. The access strategy, however, depends on the feasibil-
ity for manufacturers of a donation/non proﬁt price for
drugs and needs to be negotiated taking into account the
speciﬁc circumstances for each drug and the complexities
inherent in public–private partnerships.
As leishmaniasis is a disease prevalent in low-, middle- and
high-income countries, any strategy for access to drugs will
vary according to the circumstances and particularities of
each country, including external funding for control pro-
grammes, the disease burden within each country, and
whether governments have determined leishmaniasis as a
public health priority. For example, for the attack phase of
the elimination programme in low-income countries of the
Indian subcontinent WHO regards a large-scale donation of
AmBisome by the manufacturer as an appropriate approach,
to be employed in public health facilities and by NGOs active
in the control of VL. For programmes in low-income coun-
tries such as Sudan and Ethiopia, with large epidemics and
complex clinical management of HIV-co-infected and mori-
bund patients, WHO—with the ﬁnancial support of AECID
(Agencia Espan˜ola de Cooperacio´n Internacional Para el De-
sarrollo)—donates several drugs including antimonials, AmBi-
some and paromomycin. WHO has been able to reach, in
partnership with sanoﬁ-aventis, a preferential, not for proﬁt
price for Glucantime (meglumine antimoniate) that has sig-
niﬁcantly improved access. The price of a treatment with
Glucantime, around US$ 50 per adult treatment, and about a
third of this price for localized treatment, is similar to a
treatment with generic sodium stibogluconate (Albert David,
India) (see Table 1). Experience has shown that this price is
affordable for governments even in low-income countries,
and WHO considers it a priority that it will be maintained
over the long term. This price is used as a benchmark for
renegotiating the price of other drugs, such as miltefosine,
Pentostam (sodium stibogluconate, GlaxoSmithKline) and
AmBisome.
TABLE 1. Price per visceral leishmaniasis treatment (July
2011
Compound Treatment
regimen (days)
Drug
cost in US$a
L-Amb 10 mg/kg 1 126
L-Amb 20 mg/kg 2–4 252
Amphotericin B deoxycholate
1 mg/kg (alternating days)
30 20
MF 100 mg/day 28 65–150
PM 15 mg/kg/day 21 15
SSG 20 mg/kg/day 30 55.8
MA 20 mg/kg/day 30 59.3
L-Amb 5 mg/kg + MF 100 mg/day 8 88.2–109.5
L-Amb 5 mg/kg + PM 15 mg/kg/day 11 79
MF 100 mg/day + PM 15 mg/kg/day 10 30.2–60.7
SSG 20 mg + PM 15 mg/kg/day 17 44
L-Amb, liposomal amphotericin B; MF, miltefosine; PM, paromomycin; SSG,
sodium stibogluconate; MA, meglumine antimoniate.
aFor a patient weighing 35 kg. Calculations for SSG and MF based on exchange
rate of € 1 = US$ 1.41 (28 January 2010). Price range of miltefosine depends on
order volume. Price is based on generic SSG.
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Drug availability and proper forecasting
Most drugs for leishmaniasis are produced by only a single
manufacturer (Table 2). Agreements for the sustainability of
their production are essential and should be seen as an ethi-
cal duty. Next to that, these manufacturers require yearly
forecasts of needs to avoid irregular production, shortage,
or over-production and subsequent destruction of drugs,
which would cause them ﬁnancial damage. Such forecasts
need to be made in a collaboration between manufacturers,
countries, WHO and NGOs. Stakeholder forecast commit-
tees should be set up and coordinated by, for example,
WHO. A production plan can then be made that will safe-
guard against a lack of availability of drugs. In addition to a
production plan, the establishment of a buffer stock will
allow for a rapid response capacity to outbreaks or an unex-
pected increase in cases. Large buffer stocks inherently cre-
ate the risk of substantial drug loss as drugs may expire
while still in stock. However, this risk can be seen as tempo-
rary and will be minimized as better control efforts bring the
case load down and produce reliable surveillance data over
the years. Evidence-based forecasts also provide an impor-
tant added value to control activities: they can be used as a
tool in epidemiological surveillance and as the base for the
monitoring of efﬁcacy and drug resistance/treatment failure
in surveillance systems.
Drug distribution and storage
Continuous drug availability based on forecast systems and
buffer stocks is the most efﬁcient way to ensure successful
control of a disease. But depending on the type of agreement
between companies and stakeholders and drug management
systems, efﬁciency can vary greatly. Distribution of drugs
comes with numerous challenges. Distribution from manufac-
turers to countries should include proper storage and ship-
ment at adequate temperatures, proper stock management
(‘ﬁrst in ﬁrst out’), and correct handling and storage at cus-
toms level. Distribution from central stores at country level
to peripheral health centres is another important aspect of
access, and includes temperature management during trans-
port and storage and timely and full coverage of all con-
cerned treatment centres.
Drug quality
Some drugs for leishmaniasis are produced in countries
where the national Good Manufacturing Practice (GMP) stan-
dards are considered to be non-compliant with those deﬁned
by WHO. In the recent past, counterfeit miltefosine was dis-
tributed in control programmes in Bangladesh [20], and in
several instances, antimonial drugs of inferior quality have led
to unacceptable toxicity and death in India and South America
[21]. Centralized quality assurance and control of drugs for
leishmaniasis are lacking and should be established. Distribu-
tion of drugs through ofﬁcial institutions is one of the most
efﬁcient ways to guarantee their quality. WHO is expected to
step up in coordination and support to countries in the area
of quality assurance of drugs for leishmaniasis in the coming
years. Countries can already beneﬁt from WHO support in
identifying counterfeits and low-quality generics.
Drug legislation
Drugs for which preferential prices have been negotiated are
not always registered in low-income and middle-income
countries, because of a lack of a proﬁtable market and a low
number of patients. If drugs are not registered, special
TABLE 2. Antileishmanial drug prices (July 2011)
Compound Commercial name and manufacturer Price informationa
Amphotericin B deoxycholate Different names in different countries Variable, but median is US$ 7.5 per 50-mg vialb
Liposomal amphotericin B AmBisome, Gilead, USA
Single source
WHO negotiated price, US$ 18 per 50-mg vialc
Miltefosine Impavido, Paladin, Canada
Single source
WHO-negotiated prices:d
For adults: € 45.28–54.92 for 56 (50-mg) capsules
For children: € 34.36–39.3 for 56 (10-mg) capsules
Paromomycin Paromomycin, Gland Pharma, India
Single source
Approximate price, US$ 15 per adult course of 21 days
Sodium stibogluconate (SSG) Pentostam, GSK 66.43 GBP per vial 100 mL, 100 mg/mLe
WHO-approved generic sodium stibogluconate SSG, Albert David, India
Single source
€ 5.65 per 30-mL vial of 100 mg/mlf
Meglumine antimoniate Glucantime, Aventis
Single source
WHO-negotiated price:
US$ 1.2 per 5-mL vial of 81 mg/mL
Information on access to drugs at the WHO-negotiated price is available at www.who.int/leishmaniasis/research/en.
Costs are given by the companies in the indicated currencies that are maintained to avoid any potential variations.
aPrices as quoted by manufacturers in the currency as originally quoted.
bUNICEF. Sources and prices of selected medicines for children, 2nd edn, 2010.
cPrice valid until May 2013. The price will be re-established afterwards, with a ceiling of US$ 20 per vial.
dPrices depend on size of order.
ePrice as quoted in British National Formulary 59.
fValid for governments, United Nations organizations and non-governmental organizations.
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permission for their import is required, which may be time-
consuming and difﬁcult. Moreover, in the absence of registra-
tion, no pharmacovigilance is carried out by the manufac-
turer and rare adverse effects may go unnoticed. A wider
base of registrations of drugs for leishmaniasis in highly ende-
mic countries is needed, especially where they are included
in the national protocol. For countries with a low to very
low endemicity, rather than trying to extend the number of
registrations, agreements should be reached to facilitate the
rapid importation of unregistered drugs. Small centralized
buffer stocks should be established that can be readily
accessed for the treatment of individual patients, and prior
arrangements with customs should be made so that the
drugs can be imported swiftly when needed. All drugs for
leishmaniasis are now included in the WHO Essential Medi-
cines List, which supports Ministries of Health to authorize
their importation and implementation. National treatment
protocols, however, often do not reﬂect the latest develop-
ments, and few or no drugs for leishmaniasis are included in
national essential drug lists. WHO is encouraging govern-
ments of endemic countries to include the relevant drugs for
leishmaniasis, emphasizing that repetition of clinical studies
on their efﬁcacy in every country does not offer added value,
delays innovation and is against the beneﬁt of the patients.
Governments should consider the available clinical evidence
in a broader perspective to accelerate the implementation of
WHO-recommended treatments.
Furthermore, the implementation of strict regulations
regarding drugs at the national level should be strengthened.
Uncontrolled access to drugs for leishmaniasis (e.g. over-the-
counter availability) is common in many countries and leads
to misuse, suboptimal treatment and, in the long term, drug
resistance. The use of counterfeit medicines (fake miltefosine
and Glucantime) has led to several avoidable deaths.
User friendliness
WHO intends to cooperate with manufacturers to develop
appropriate packing and information leaﬂets, which will facili-
tate implementation in ﬁeld circumstances.
Main Problems Per Individual Drug and
Proposed Solutions
AmBisome (liposomal amphotericin B)
Following an agreement that was signed in May 2007
between Gilead and WHO, Gilead offers AmBisome for a
no-proﬁt-no-loss price of US$ 18/vial for the treatment of
visceral and mucosal leishmaniasis within the public sector of
developing countries. The price will be re-established yearly,
but will never exceed US$ 20/vial. As Gilead holds sizable
stocks to serve the international market, orders can be des-
patched within 2 weeks. AmBisome is produced under GMP
standards that are equivalent to WHO GMP.
Although there are no quality and supply problems, the
price of AmBisome remains a major barrier for access.
Treatment regimens involving AmBisome are relatively
expensive compared with other treatments. For India, calcu-
lations showed that the price would need to be lower than
US$ 10/vial for its cost-effectiveness to be comparative to
other regimens [22]. A successful scenario to create access
to AmBisome would be to make it available at a price of
US$ 10/vial or lower in the Indian subcontinent, and as a
donation for the attack phase of the elimination plan in Ban-
gladesh, a low-income country with a high VL burden that is
unable to afford even this price.
For the East African region, AmBisome is used as a sec-
ond-line treatment for the management of complex VL
patients. The recommended AmBisome regimen is expensive
(Table 1). Ideally AmBisome should be made available as a
donation for compassionate use in endemic sub-Saharan Afri-
can countries.
AmBisome is registered in India and Brazil, and submitted
for registration in Bangladesh and Ethiopia.
As AmBisome should not be kept at high temperatures to
prevent the melting of liposomes, Gilead is encouraged by
WHO to explore novel solutions to ensure a ‘cool chain’
under ﬁeld circumstances.
Pentavalent antimonials
The two forms of pentavalent antimonials, meglumine antimo-
niate and SSG, are chemically similar but differ in the dose
administered, i.e. 8.1% Sb5+ (81 mg/mL) versus 10% Sb5+
(100 mg/mL). As a result of this difference, the two forms
cannot easily be substituted within control programmes.
Glucantime (meglumine antimoniate). Glucantime is supplied
by sanoﬁ-aventis for a no-proﬁt no-loss price of US$ 1.2/vial
for the treatment of leishmaniasis for public sector agencies of
developing countries. This agreement is valid indeﬁnitely. The
company has expressed willingness to continue production for
as long as necessary and currently holds a large buffer stock in
coordination with WHO, to cover increased demands during
the epidemic season in East Africa. Glucantime is produced
under GMP standards that are equivalent to WHO GMP.
There are no issues with supply, quality and price of Glu-
cantime. Recently, the preferential price has been extended
to the Balkan region and post-Soviet States.
Glucantime is not registered in all countries where VL and
CL are highly endemic and where antimonials are used as
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ﬁrst-line drugs, with registrations lacking especially in East
Africa and the Middle East.
Generic SSG (Albert David). Albert David (Calcutta, India) is
the only producer of generic SSG worldwide. The price of
generic SSG is comparable to the price of Glucantime
(Table 1); however, no agreement has been made about the
sustainability of this price. Albert David has currently no
intention of stopping production, but it should be noted that
the commercial market for generic SSG is relatively small. It
is currently only in use in control programmes in Ethiopia,
Sudan and Afghanistan, and therefore, the sustainability of
production is not guaranteed and deserves special attention.
Albert David may occasionally hold a buffer stock, but its
size varies. A continuous and sizable buffer stock of SSG
accessible for NGOs and control programmes is critically
needed as it is used as a ﬁrst-line treatment in large out-
breaks in Sudan and Ethiopia. The need for and size of a buf-
fer stock of generic SSG should be established.
Since 2004, quality problems and a lack of adherence to
international GMP standards have caused frequent and in
some cases disastrous interruptions of supply to control pro-
grammes. The quality of generic SSG remains an ongoing
concern. Regular GMP audits and batch-by-batch quality con-
trol are essential to ensure and control drug quality. The
WHO Prequaliﬁcation Programme intends to take the lead
in quality assurance of generic SSG.
Generic SSG is not registered in all highly endemic coun-
tries for VL and CL where it is commonly used. Although it
is registered in Kenya and Uganda, further registrations are
needed in Sudan, Ethiopia and Afghanistan.
Pentostam (SSG). Access to Pentostam is poor, as Glaxo-
SmithKline (GSK) does not offer a preferential price for low-
income and middle-income countries. Treatment with Pento-
stam is much more expensive than with other antimonials
(Table 2). GSK intends to eventually stop the production of
Pentostam, which will further reduce access to antimonials.
Pentostam is the only form of SSG produced under GMP
standards equivalent to WHO GMP.
Ideally, the production of Pentostam should not cease and
its price should become comparable to that of generic SSG
and Glucantime. If production ceases, technology transfer to
Albert David, India (the only producer of generic SSG), with
the aim of assuring a continuous availability of quality-assured
generic SSG, may be an appropriate approach.
GSK does not hold a buffer stock of Pentostam. Adequate
responsiveness with Pentostam is not possible in case of out-
breaks because of a low production capacity (2000 vials/batch)
and lead times for orders of several months. Negotiation with
GSK to hold a buffer stock for urgent needs that cannot be
covered with Glucantime or generic SSG is necessary.
Pentostam is not registered in all highly endemic countries
where antimonials are ﬁrst-line drugs. The necessity of new
registrations will depend on its future price and availability.
Paromomycin
Paromomycin is currently the cheapest drug for VL. There is
an agreement in place between Gland Pharma, India (the man-
ufacturer of paromomycin) and the non-proﬁt Institute of
One World Health regarding the price and sustainability of
production worldwide [23]. However, as there is currently no
commercial market for paromomycin, sustainability of produc-
tion may eventually be compromised and needs to be assured.
The current demand for paromomycin is low and produc-
tion is irregular. Gland Pharma does not hold a buffer stock
of paromomycin. A sizable buffer stock of paromomycin
accessible for control programmes and NGOs is essential
and urgently needed because this product is used as ﬁrst-line
co-treatment in Sudan in large outbreaks.
Quality problems recently led to a supply gap of over
1 year. As the quality of paromomycin remains an ongoing
concern, regular audits and quality control are essential to
ensure continuous quality. As with generic SSG, the WHO
Prequaliﬁcation Programme intends to take the lead in qual-
ity assurance of paromomycin.
Paromomycin is registered in India, with plans for registra-
tion in Bangladesh and Nepal in 2011 and African countries
in 2011–2012. No additional registrations are foreseen to be
necessary in the near future.
TABLE 3. Speciﬁc access strategy per drug as proposed by WHO
Drug Aim of access strategy
AmBisome A donation to speciﬁc countries + price decrease to US$ 10/vial for India
Miltefosine Preferential price decreased to US$ 50/adult treated; sustain production;
decrease order lead time; facilitate access to small quantities
Paromomycin Sustain production and price; extend base of registrations; facilitate access
to small quantities; assure quality.
Glucantime Sustain price and production; extend base of registrations
Generic SSG (Albert David) Sustain price and production; assure quality; extend base of registrations
Pentostam Sustain production; preferential price of 50 USD/adult treated
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Miltefosine
Miltefosine was developed by Zentaris (Frankfurt, Germany),
in close cooperation with WHO/Special Programme for
Research & Training in Tropical Diseases (TDR). Currently, it
is manufactured by Paladin (Que´bec, Canada), after the rights
of production and marketing were obtained from Zentaris.
Miltefosine is produced under GMP standards that are equiva-
lent to WHO GMP. Following negotiations between Zentaris
and TDR, miltefosine was made available to developing coun-
tries for the production price plus a mark up. As the current
price is relatively high compared with other treatments
(Table 1) negotiations for a new and reduced preferential
price are needed. WHO will aim for a price per treatment
similar to a treatment with generic SSG and Glucantime
(around US$ 50/treatment), valid for all endemic low-income
and middle-income endemic countries and an agreement to
maintain the production for as long as is necessary.
Demand for miltefosine is low and production is irregular
and it is not clear if Paladin holds a buffer stock. This, and
lead times for orders, should be clariﬁed.
Miltefosine is registered in India, Bangladesh, Nepal and
Pakistan with agreements in place for registration in African
countries. Additional registrations are not foreseen to be
necessary in the near future.
The speciﬁc strategies for access for each drug are sum-
marized in Table 3.
Conclusion
The solutions proposed in this publication should signiﬁcantly
improve access to drugs for leishmaniasis and are practical,
feasible and long overdue. Past efforts by WHO and NGOs
have resulted in lower drug prices but lacked coordination
and did not take all aspects regarding drug access into account.
A concerted effort by all stakeholders is needed to achieve an
improved access to drugs. Overall monitoring of access to
anti-leishmanial drugs should be strengthened, with pricing,
quality, registration and global needs taken into account.
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